Senators Allege That Drug Companies Paid To Help Get Approval For A Dangerous New Painkiller
AP
Now, two senators are questioning the ethics of a series of meetings between drug companies and federal regulators, MedPage Today reports.
Senators Joe Manchin (D-W.Va.) and David Vitter (R-La.) want answers about what they call "pay-to-play" meetings in which pharmaceutical manufacturers allegedly shelled out thousands of dollars to meet with FDA officials who oversee safety regulations on painkillers. The senators suggest these meetings might have helped Zohydro get approved by the FDA despite an advisory committee voting against it.
The FDA approved Zohydro in the fall, and it's expected to be available to patients with chronic pain starting in March. Dozens of doctors and addiction treatment groups are calling for the FDA to revoke its approval of the drug, which they say is deadly and could lead to another spike in opioid addiction.
Opponents of the drug argue that it will be prone to abuse because the pills contain a high dose of hydrocodone, a narcotic that has effects similar to heroin, and they're reportedly easy to crush or chew for addicts who want to get a strong high quickly.
The senators want to see financial records - including any payment transfers - for groups connected to the University of Rochester that reportedly set up the meetings between drug company representatives and FDA officials, according to MedPage Today.
Zohydro's initial manufacturer, Elan (now Alkermes), reportedly paid to send a representative to these private meetings. (The drug is marketed in the U.S. by a third company, Zogenix.)
In their letter, the senators allege these meetings gave the drug companies "undue influence over FDA's approval process for prescription painkillers."
University of Rochester Medical Center spokesman Christopher DiFrancesco denied to MedPage Today that these were "pay-to-play" meetings. He said participants were not allowed to discuss specific drugs and that the meetings had no bearing on the FDA's decisions about whether or not to approve certain drugs.
- Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- One of the world's only 5-star airlines seems to be considering asking business-class passengers to bring their own cutlery
- Experts warn of rising temperatures in Bengaluru as Phase 2 of Lok Sabha elections draws near
- Axis Bank posts net profit of ₹7,129 cr in March quarter
- 7 Best tourist places to visit in Rishikesh in 2024
- From underdog to Bill Gates-sponsored superfood: Have millets finally managed to make a comeback?
- 7 Things to do on your next trip to Rishikesh